and preclinical studies revealing that IGF-1R is overexpressed in SCCHN, we have yet to find an effective way to exploit this molecular pathway. Results from Phase II head and neck cancer studies ...

Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the presentation of ...

DelveInsight’s “TEPEZZA Market Size, Forecast, and Market Insight Report” highlights the details around TEPEZZA, an insulin-like Growth Factor-1 receptor (IGF-1R) inhibitor. The report ...